Vincent Miles

Investor

Boston, Massachusetts

Writes $15M – $30M checks · typically $22.5M

About

Vincent Miles is an Executive Director at Abingworth, which he joined in 2007, where he helps identify and evaluate new business opportunities and supports portfolio companies. He previously served as Senior Vice President of Business Development at Alnylam Pharmaceuticals and held VP roles at Millennium Pharmaceuticals, and earlier led the technology transfer office at the Dana-Farber Cancer Institute and held positions at RiboGene, Pharmacia, and Amersham International. He holds a BSc in Biochemistry and a PhD in Biochemical Embryology from University College London.

LinkedIn ↗

Invests in

Biotech

Experience

AbingworthExecutive Directorcurrent2022 — presentGreater Boston
AbingworthPartner2007 — 2022Boston, Massachusetts, United States
Alnylam PharmaceuticalsSenior VP, Business Development2003 — 2007
Millennium PharmaceuticalsVP, Business Development, Technology Management1997 — 2003
Dana Farber Cancer InstituteDirector, Office of Technology Transfer1996 — 1997
RiboGene (a predecessor of Questcor)VP, R&D and Business Development1992 — 1996
Pharmacia BiotechVP, International Marketing (Molecular Biology Division)1989 — 1992
Pharmacia BiotechVP, R&D (Molecular Biology Division)1986 — 1990
Amersham InternationalR&D and Business Development1978 — 1986
Home Office Forensic Science LaboratoryHigher Scientific Officer1975 — 1978

Education

UCLB.Sc. (biochemistry), Ph.D. (biochemical embryology/molecular biology)1969 — 1975

Skills & more

Strategic Planning3Strategy4Management1R&D23Business Development22Commercialization8Technology Transfer27Start-ups7Biology2Licensing5Corporate Development8Competitive Analysis3

+12 more

Venture CapitalMergersLifesciencesBiotechnologyDue DiligenceEntrepreneurshipPharmaceutical IndustryOncologyBusiness PlanningBusiness StrategyMergers & AcquisitionsDrug Development

From Vincent's professional profile.

Same school

Also attended UCL253

André DuboisInvestor at Index Ventures Frédérique DameInvestor at GV (Google Ventures)Jonas VetterleInvestor at Moonfire Ventures Marie FerriInvestor at Daphni Elena PantaziPartner & Head of Platform at Northzone Giovanni MariggiInvestor at Medicxi

+ 247 more

Shared employers

Also worked at Abingworth17

Carlos PayaVenture Partner at Ysios Capital Sarah ShackeltonAdvisor at Delin Ventures Bali MuralidharGlobal Head of Life Sciences & CIO at Abingworth Kurt von EmsterManaging Partner at Abingworth Jayson PunwaniManaging Director, Head of Venture at Abingworth Andrew SinclairManaging Director, Head of Publics & Late Stage at Abingworth

+ 11 more

Also worked at Alnylam Pharmaceuticals5

Kevin StarrInvestor at Third Rock Ventures Jason RhodesPartner at Atlas Venture Eric HuangPartner at Delos Capital Helen KeshishianInvestor at Huntington Angels Network John ConleyBoard Member at Launchpad Venture Group

Also worked at Millennium Pharmaceuticals25

Kevin MunnellyInvestor at Third Rock Ventures John KeiltyVenture Partner at Third Rock Ventures Kevin GillisPartner and Chief Operating Officer at Third Rock Ventures Kevin StarrInvestor at Third Rock Ventures Neil ExterRetired Partner at Third Rock Ventures Robert TepperPartner and co-founder of Third Rock Ventures

+ 19 more

Also worked at Dana Farber Cancer Institute26

Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Dave BarrettSenior Advisory Partner at Polaris Partners Weihan LiuAssociate at Cure Ventures Rosie BellDirector of Marketing at LRVHealth Taruho KurodaImpact Partner at Fresco Capital BeccaInvestor at Sanofi Ventures

+ 20 more

Investments

Board seats

Atsena TherapeuticsBrave BioChiasmaDicerna PharmaceuticalsDynex TechnologiesHydra BiosciencesIFM DueIFM TherapeuticsIFM TreMagellan DiagnosticsNido BiosciencesPersonalisPrimeraDx

Per the firm's website.